CaPtivate Pharmaceuticals
Small biotechnology company developing a calcium phosphate nanoparticle adjuvant and delivery platform for human and veterinary vaccines. Activities described include preclinical development across multiple antigens, formulation for parenteral and mucosal administration (including intranasal dry-powder formats), pilot-scale GMP manufacturing of inorganic nanoparticles, and partnering/licensing or material transfer for external vaccine programs.
Industries
Nr. of Employees
small (1-50)
CaPtivate Pharmaceuticals
Doylestown, Pennsylvania, United States, North America
Products
Calcium phosphate nanoparticle adjuvant platform
A biodegradable calcium phosphate nanoparticle platform used as a vaccine adjuvant and delivery system designed to enhance humoral, cellular, and mucosal immune responses and enable dry-powder formulations.
Nasal influenza vaccine formulations (preclinical)
Preclinical development of inactivated influenza virus vaccines formulated for intranasal delivery, including powder formulations and studies against seasonal and pandemic strains.
CaP tiVax
Calcium Phosphate Nanoparticle Vaccine Adjuvant technology offering a safe and effective platform for delivering drugs or vaccines and enhancing immune response to viral, bacterial, or parasitic antigens.
CaPtivate Vaccine Adjuvants
Nanoparticle-based vaccine adjuvant technology designed to enhance immune responses, stimulate cellular or Th1-type immunity, and support mucosal administration.
CaPtivate's nanoparticles
Proprietary nanoparticle technology designed to act as a safe, non-toxic, and effective vaccine adjuvant and delivery system capable of inducing optimized B cell and appropriate T-cell responses.
Mucosal Herpes Simplex-2 (HSV-2) Vaccine Formulation
A preclinical mucosal vaccine candidate utilizing calcium phosphate (CaP) nanoparticles as an adjuvant to deliver HSV-2 antigen for enhanced protective systemic and mucosal immunity.
Calcium phosphate nanoparticle adjuvant platform
A biodegradable calcium phosphate nanoparticle platform used as a vaccine adjuvant and delivery system designed to enhance humoral, cellular, and mucosal immune responses and enable dry-powder formulations.
Nasal influenza vaccine formulations (preclinical)
Preclinical development of inactivated influenza virus vaccines formulated for intranasal delivery, including powder formulations and studies against seasonal and pandemic strains.
CaP tiVax
Calcium Phosphate Nanoparticle Vaccine Adjuvant technology offering a safe and effective platform for delivering drugs or vaccines and enhancing immune response to viral, bacterial, or parasitic antigens.
CaPtivate Vaccine Adjuvants
Nanoparticle-based vaccine adjuvant technology designed to enhance immune responses, stimulate cellular or Th1-type immunity, and support mucosal administration.
CaPtivate's nanoparticles
Proprietary nanoparticle technology designed to act as a safe, non-toxic, and effective vaccine adjuvant and delivery system capable of inducing optimized B cell and appropriate T-cell responses.
Mucosal Herpes Simplex-2 (HSV-2) Vaccine Formulation
A preclinical mucosal vaccine candidate utilizing calcium phosphate (CaP) nanoparticles as an adjuvant to deliver HSV-2 antigen for enhanced protective systemic and mucosal immunity.
Services
Formulation of vaccine antigens with calcium phosphate nanoparticles for parenteral or mucosal administration and provision of material for partner evaluation under MTAs or collaborative agreements.
Formulation of vaccine antigens with calcium phosphate nanoparticles for parenteral or mucosal administration and provision of material for partner evaluation under MTAs or collaborative agreements.
Expertise Areas
- Vaccine adjuvant development
- Nanoparticle-based antigen delivery
- Mucosal (intranasal) vaccine formulation
- Thermostable dry-powder vaccine development
Key Technologies
- Calcium phosphate nanoparticle platform
- Mucosal (intranasal) vaccine delivery
- Thermostable dry powder (freeze-dried) formulations
- Antigen adsorption to inorganic nanoparticles
News & Updates
Conducted a Phase I human safety and toxicity study under an IND in the USA; administered formulation reported as non-inflammatory, non-toxic, and non-reactogenic.
Conducted a Phase I human safety and toxicity study under an IND in the USA; administered formulation reported as non-inflammatory, non-toxic, and non-reactogenic.